NEW YORK, May 20, 2025 /PRNewswire/ — With healthcare organizations facing mounting regulatory scrutiny and evolving data security threats, compliance has never been more critical. Compliancy Group is proud to announce its latest educational webinar: “From Risk Identification to Remediation: A Proactive Approach to Compliance,” designed to equip compliance professionals with the tools and strategies needed to assess, manage, and remediate compliance risks effectively.
Scheduled for May 28th at 1 PM ET, this live, expert-led session walks attendees through the entire lifecycle of a compliance risk assessment—from identifying vulnerabilities to implementing corrective actions that fortify both data security and operational integrity.
Attendees will gain:
Whether you’re part of a compliance team, IT department, or healthcare administration, this session offers the knowledge and confidence needed to build a stronger compliance program.
Secure your spot today and take the first step toward a more secure and compliant future. Register Now!
About Compliancy Group
Compliancy Group empowers healthcare organizations to confidently tackle regulatory compliance challenges with user-friendly, customizable software. Our robust toolset streamlines compliance management, from tracking requirements and generating reports to managing incidents and analyzing organizational risks. With a simplified approach, we help reduce stress, improve patient trust, and enhance profitability. Endorsed by leading medical associations, Compliancy Group is the trusted solution for healthcare compliance. Discover how we can simplify compliance for your organization today!
Media Contact: info@compliancygroup.com
SOURCE COMPLIANCY GROUP
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…